Comparison guide · Reviewed May 2026
Semaglutide vs Tirzepatide — Liver Health Comparison
Semaglutide and tirzepatide are the two dominant GLP-1 medications in Australia. Both improve liver health. But they differ in mechanism, the maturity of their liver evidence base, and their Australian regulatory status for liver disease.
This is the clinical comparison — for patients and GPs who want to understand the difference between the two drugs specifically for liver health.
Published 2026-05-01 · Clinically reviewed 2026-05-31
Comparison guide · Reviewed May 2026
Understanding the Names
Semaglutide is the active ingredient in both Ozempic (1mg weekly, approved for type 2 diabetes) and Wegovy (2.4mg weekly, approved for weight management and…
Semaglutide is the active ingredient in both Ozempic (1mg weekly, approved for type 2 diabetes) and Wegovy (2.4mg weekly, approved for weight management and MASH).
Tirzepatide is the active ingredient in Mounjaro (approved for weight management and OSA in Australia).
The brand names are marketing — the clinical comparison is between semaglutide and tirzepatide.
The Mechanism Difference
Semaglutide: Single GLP-1 receptor agonist. Activates one receptor — GLP-1 — to produce its metabolic and hepatic effects.
Tirzepatide: Dual GLP-1 and GIP receptor agonist. Activates two receptors simultaneously. GIP receptor activation adds additional metabolic effects — improved lipid metabolism, enhanced insulin secretion, and potentially direct GIP receptor-mediated effects on liver fat metabolism.
Both GLP-1 and GIP receptors are expressed in liver tissue. Tirzepatide's dual mechanism may produce additive hepatic benefits — but whether this translates to superior liver histology outcomes compared to semaglutide remains to be confirmed in completed head-to-head liver data.
Comparison guide · Reviewed May 2026
The Evidence Base — Where Each Drug Stands
Semaglutide — the ESSENCE trial:
Semaglutide — the ESSENCE trial:
The phase 3 MASLD-specific trial. Published NEJM May 2025. 800 participants across 37 countries. 72 weeks. Semaglutide 2.4mg weekly vs placebo in patients with biopsy-confirmed MASH and F2–F3 fibrosis.
- 62.9% MASH resolution without worsening fibrosis vs 34.3% placebo
- Fibrosis improvement by at least one stage: 37.0% vs 22.4% placebo
This is the definitive liver disease dataset for semaglutide. The TGA approved Wegovy for MASH treatment in April 2026 based on this evidence.
Tirzepatide — the SYNERGY-NASH trial:
The dedicated liver disease trial for tirzepatide. Completed enrolment 2025 with results expected 2026. No published primary endpoint data available at time of writing.
Phase 2 data: Significant liver fat reduction and liver enzyme improvement in patients with MASLD. Broadly positive signals consistent with a disease-modifying hepatic effect.
The honest position: Semaglutide has the mature, published, TGA-reviewed phase 3 liver data. Tirzepatide does not yet. When SYNERGY-NASH publishes, this comparison will become much clearer.
Weight Loss and Its Liver Implications
Liver fat reduction closely tracks weight loss magnitude. More weight loss means more liver fat reduction.
Tirzepatide produces approximately 20–22% weight loss versus 14–17% for semaglutide at 2.4mg. This weight loss advantage translates directly to a liver fat reduction advantage — tirzepatide would be expected to produce greater liver fat reduction on average based on weight loss magnitude alone.
The ESSENCE trial showed benefits beyond weight loss — semaglutide's hepatic effects were not fully explained by the degree of weight reduction. Tirzepatide may have similar direct hepatic effects, plus the GIP receptor contribution. But this is mechanistic reasoning, not confirmed phase 3 liver histology data.
Comparison guide · Reviewed May 2026
TGA Regulatory Status for Liver Disease
For patients who need a TGA-approved liver disease treatment today: semaglutide (Wegovy at 2.4mg) is the only option. Tirzepatide may join it after…
| Semaglutide (Wegovy) | Tirzepatide (Mounjaro) | |
|---|---|---|
| TGA liver indication | ✓ Provisional April 2026 | ✗ None (SYNERGY-NASH pending) |
| Indication | MASH F2–F3, non-cirrhotic | — |
| Prescribing requirement | Specialist involvement | — |
For patients who need a TGA-approved liver disease treatment today: semaglutide (Wegovy at 2.4mg) is the only option. Tirzepatide may join it after SYNERGY-NASH results.
Practical Guidance
Use semaglutide if:
- You have confirmed MASH at F2–F3 requiring TGA-approved treatment now
- You are already on Ozempic for T2D and want the most cost-effective liver benefit
- You want the most comprehensively evidenced liver treatment
Consider tirzepatide if:
- Maximum weight loss is the primary goal alongside liver benefit
- You have not responded adequately to semaglutide
- You are prepared to await SYNERGY-NASH data for the definitive liver comparison
Find a liver elastography clinic near you
Search by suburb or postcode to see accredited clinics offering FibroScan and guided liver elastography across Australia.
Type a suburb or postcode and press Enter to search nearby.
Request a liver scan appointment
Submit your details and we'll route your request to the most appropriate elastography clinic in your area. Most clinics respond within 1–2 business days.
Take action
Request an appointment
Frequently asked questions
Is tirzepatide better than semaglutide for fatty liver?
No head-to-head liver histology data exists. Tirzepatide produces more weight loss on average, which is expected to produce greater liver fat reduction. Semaglutide has the more mature and definitive liver-specific evidence. SYNERGY-NASH results (2026) will clarify the comparison.
Which drug is approved for liver disease in Australia?
Wegovy (semaglutide 2.4mg) received TGA provisional approval for non-cirrhotic MASH with F2–F3 fibrosis in April 2026. Mounjaro (tirzepatide) does not yet have a liver disease indication in Australia.
Does the dose matter for liver benefits?
Yes — GLP-1 liver benefits are dose-dependent. Wegovy at 2.4mg produces greater liver benefit than Ozempic at 1mg. The weight loss advantage of tirzepatide at 15mg over semaglutide at 2.4mg suggests greater liver fat reduction at maximum doses.
ESSENCE NEJM May 2025; SYNERGY-NASH trial status 2025; TGA provisional approval April 2026; SURMOUNT-5 NEJM May 2025; AASLD Practice Guidance November 2025.
This article is for educational purposes only. It does not constitute medical advice. Always consult your GP or a specialist about your individual health circumstances.
Next step
Find a liver elastography clinic near you
Search participating clinics across Australia, or talk to your GP about a baseline FIB-4 and elastography.